Uses computational biology to discover and develop novel agricultural biotechnology products, aiming to enhance crop productivity and sustainability.
Evogene Ltd. operates as a leading computational biology company, driving innovation in product discovery and development across diverse life-science sectors such as human health and agriculture. Central to its approach is the Computational Predictive Biology (CPB) platform, which integrates deep biological insights with big data and artificial intelligence. This platform enables Evogene to computationally discover and guide the development of novel life-science products, including microbes, small molecules, and genetic elements.
The company operates through three main segments: Agriculture, Human Health, and Industrial Applications. Within Agriculture, Evogene focuses on enhancing plant performance through the development of seed traits, agricultural chemicals, and biological products tailored for major crops like corn, soybean, and cotton. In the Industrial Applications segment, Evogene develops advanced castor bean seeds designed as a sustainable feedstock for industrial purposes. The Human Health segment is dedicated to discovering microbiome-based therapeutics targeting immuno-oncology, gastrointestinal disorders, and antimicrobial resistance.
Founded in 1999 and headquartered in Rehovot, Israel, Evogene has established a global presence with operations spanning the United States, Israel, Brazil, and beyond. The company collaborates strategically with industry leaders such as BASF SE, Corteva, and Bayer, leveraging its expertise to pioneer groundbreaking solutions in agriculture and biopharmaceuticals. Through its subsidiary Canonic Ltd., Evogene also collaborates with Cannbit Ltd. to develop innovative medical cannabis products, underscoring its commitment to exploring new frontiers in healthcare and sustainable agriculture.